COMP <GO>
SER vs ELTX // FORWARD P/E MULTIPLE
Serina Therapeutics Inc. (NYSE) VS. Elicio Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SER 2
— ELTX 0
■ METRIC PARITY
LAST: $1.94 (+2.65%) • MKT CAP: $48.0M
forward-pe
—
LAST: $1.68 (-4.00%) • MKT CAP: $47.4M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SER VS. ELTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SER | ELTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 132.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 45.0 | +4.80 | SER | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.0M | $47.4M | $597.3K | SER | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SER REV | ELTX REV | SER GROSS % | ELTX GROSS % | SER FCF | ELTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $130.0K | $0 | — | — | -$18.0M | -$37.0M |
| FY 2024 | $56.0K | $0 | — | — | -$17.2M | -$37.2M |
| FY 2023 | $3.2M | $0 | — | — | -$2.5M | -$32.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SER // BETA —
ELTX // BETA —